Tuesday, May 11, 2021 11:28:13 AM
Yeah, a lot of balls in the air.
That is the exact opposite of "Focus"
They talked about the Philippines in Dec 2020...nothing then, shifted to Canada after the CD12 results released ( Not completely successful) and put the Canadian Interim order as a quicker possibility.
Didn't happen, and now Canada on the back burner after Hyping the CMC filing. " Its the hardest part " now dropped the ball on the easier portion. Most likely wont happen. Waiting on CD16/CD17 results if ever.
Then back to the Philippines where the first CSP was hyped. Then 28 CSPs hyped then nothing. We are waiting on news on the 28 and waiting.
Now they claim CSP treatments for 100 patients at all Hospitals and up to 1000 Hospitals, but instead of releasing actual numbers and amount of LL shipped, sold to be stored in those Hospitals for CSP. Instead of announcing the amount earned, they don't release any info on that either.
Instead, they now begin talking about an EUA, oh but it will have to wait.
Now people are talking about India, and Malaysia.
As far as what the company has told us, we had 3 people in the Philippines treated, CSP #1, the ex-President and the guy on Sunday. 3 CONFIRMED that's it.
Now the company has moved on to other things to focus on or actually to not focus on.
Message to NP and SK and others.
PICK ONE THING...START TO FINISH...
It seems to me CYTODYN the company has a problem with Attention Deficit Disorder.
ONE THING ! COMPLETE IT ! ITS NOT AN IMPOSSIBILITY ! ITS ACTUALLY WHAT PEOPLE DO IN THE WORLD.
jmo
That is the exact opposite of "Focus"
They talked about the Philippines in Dec 2020...nothing then, shifted to Canada after the CD12 results released ( Not completely successful) and put the Canadian Interim order as a quicker possibility.
Didn't happen, and now Canada on the back burner after Hyping the CMC filing. " Its the hardest part " now dropped the ball on the easier portion. Most likely wont happen. Waiting on CD16/CD17 results if ever.
Then back to the Philippines where the first CSP was hyped. Then 28 CSPs hyped then nothing. We are waiting on news on the 28 and waiting.
Now they claim CSP treatments for 100 patients at all Hospitals and up to 1000 Hospitals, but instead of releasing actual numbers and amount of LL shipped, sold to be stored in those Hospitals for CSP. Instead of announcing the amount earned, they don't release any info on that either.
Instead, they now begin talking about an EUA, oh but it will have to wait.
Now people are talking about India, and Malaysia.
As far as what the company has told us, we had 3 people in the Philippines treated, CSP #1, the ex-President and the guy on Sunday. 3 CONFIRMED that's it.
Now the company has moved on to other things to focus on or actually to not focus on.
Message to NP and SK and others.
PICK ONE THING...START TO FINISH...
It seems to me CYTODYN the company has a problem with Attention Deficit Disorder.
ONE THING ! COMPLETE IT ! ITS NOT AN IMPOSSIBILITY ! ITS ACTUALLY WHAT PEOPLE DO IN THE WORLD.
jmo
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
